Radius Appoints Scott Briggs as Chief Executive Officer

Cambridge, Mass., October 12, 2022 – Radius, Inc. today announced the appointment of Scott Briggs as Chief Executive Officer and a member of the Board of Directors. Mr. Briggs is a senior pharmaceutical commercial executive with over 25 years’ experience in pharmaceutical marketing and sales, strategic planning, and business management. Scott most recently served as Chief Commercial Officer of Sebela Pharmaceuticals, a specialty pharmaceutical company with market leading brands in gastroenterology, women’s health, and dermatology. In this role he led all commercial functions, substantially growing sales of its branded products, planned, and successfully implemented multiple product launches and acted as a senior member of the Executive Leadership team. Mr. Briggs will succeed Kelly Martin, who served as Radius’ Chief Executive Officer from May 2020 to August this year when the company was taken private by Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”).

“I am very excited to welcome Scott as Chief Executive Officer of Radius. Scott’s decades of industry experience and proven track record of launching and commercializing pharmaceutical products make him the ideal leader for the next phase of Radius’ growth,” said Travis Wilson, Partner at Gurnet Point. “Scott is uniquely qualified to step into the leadership role and Radius will benefit from his experience of being instrumental in helping companies build successful portfolio of products across a number of therapeutic areas.”

“I join my colleagues in welcoming Scott to Radius,” said Alex Albert, Founding Partner at Patient Square. “Scott’s long-term vision will position Radius to continue improving the lives of patients and expanding access to TYMLOS, the Company’s important lead therapeutic.”

“I am honored for the opportunity to be part of the Radius team to help build on the successes and trajectory the team have established,” said Scott Briggs, Chief Executive Officer of Radius. “With the financial backing and support of Gurnet Point and Patient Square, I look forward to building out the company and improving the lives of patients as we focus on accelerating the growth of TYMLOS, preparing for a potential commercial launch of the male indication for TYMLOS in the US, and continuing to invest in our organization to optimize current and future product opportunities.”

Prior to joining Sebela Pharmaceuticals, Mr. Briggs served as Vice President, Marketing and Sales at Noven Pharmaceuticals, where he led all commercial operations. Previously, he also served Noven in the roles of Vice President – women’s health sales, and Executive Director – marketing and managed markets. Prior to joining Noven, Scott was senior director of marketing for JDS Pharmaceuticals. He also held several leadership positions in management and marketing with Ortho-McNeil Pharmaceuticals (part of Johnson & Johnson). Mr. Briggs holds a BA in Business Administration from Villanova University.

About Radius
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group.

About Gurnet Point Capital
Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point’s team of highly experienced industry executives work closely with its portfolio companies, with an active approach driving operational transformation and outsized returns. www.gurnetpointcapital.com

About Patient Square Capital
Patient Square Capital (www.patientsquarecapital.com) is a dedicated health care investment firm that partners with best-in-class management teams whose products, services and technologies improve health. Patient Square utilizes deep industry expertise, a broad network of relationships and a true partnership approach to make investments in companies grow and thrive. Patient Square invests in businesses that strive to improve patient lives, strengthen communities, and create a healthier world. Patient Square’s team of industry-leading executives is differentiated by the depth of focus in health care, the breadth of health care investing experience, and the network it can activate to drive differentiated outcomes.

Media Contact:

Gurnet Point Capital
Tom Johnson / Blair Hennessy
Abernathy MacGregor
Email: [email protected] / [email protected]
Phone: (212) 371-5999

Patient Square Capital
Doug Allen / Zach Kouwe
Dukas Linden Public Relations
Phone: (646) 722-6530